{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:09:08Z","timestamp":1761523748295},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-018-0581-1","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:24:23Z","timestamp":1520987063000},"page":"696-701","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"Motohiro","family":"Tamiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Shigeoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunimitsu","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(00)82038-3","volume":"355","author":"PC Hoffman","year":"2002","unstructured":"Hoffman PC, Mauer AM, Vokes EE (2002) Lung cancer. Lancet 355:479\u2013485","journal-title":"Lancet"},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227\u20131234","journal-title":"J Clin Oncol"},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/1471-2407-12-327","volume":"12","author":"M Takeda","year":"2012","unstructured":"Takeda M, Okamoto I, Yamanaka T, Nakagawa K, Nakanishi Y (2012) Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L). BMC Cancer 12:327","journal-title":"BMC Cancer"},{"key":"581_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734\u2013743","journal-title":"N Engl J Med"},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, \u00d6sterlund P, Greil R, Van Cutsem E, von Moos R, Vi\u00e9itez JM, Bouch\u00e9 O, Borg C, Steffens CC, Alonso-Ordu\u00f1a V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andr\u00e9 T, Kubicka S, ML18147 Study Investigators (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"581_CR8","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902\u20132908","journal-title":"J Clin Oncol"},{"key":"581_CR9","first-page":"437","volume":"111","author":"S Sliesoraitis","year":"2011","unstructured":"Sliesoraitis S, Tawfik B (2011) Bevacizumab-induced bowel perforation. J Am Osteopath Assoc 111:437\u2013441","journal-title":"J Am Osteopath Assoc"},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577\u2013582","journal-title":"Ann Oncol"},{"key":"581_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559\u2013568","journal-title":"Lancet Oncol"},{"key":"581_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11912-012-0238-8","volume":"14","author":"T Abu-Hejleh","year":"2012","unstructured":"Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR (2012) Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14:277\u2013284","journal-title":"Curr Oncol Rep"},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","volume":"32","author":"RA Burger","year":"2014","unstructured":"Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 32:1210\u20131217","journal-title":"J Clin Oncol"},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"581_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","volume":"30","author":"M Tamiya","year":"2013","unstructured":"Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Kawase I, Hirashima T (2013) Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 30:676","journal-title":"Med Oncol"},{"key":"581_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00280-012-2026-4","volume":"71","author":"K Kitamura","year":"2013","unstructured":"Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A (2013) Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol 71:457\u2013461","journal-title":"Cancer Chemother Pharmacol"},{"key":"581_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10637-008-9162-z","volume":"27","author":"E Schellhaas","year":"2009","unstructured":"Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U (2009) Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Investig New Drugs 27:184\u2013187","journal-title":"Investig New Drugs"},{"key":"581_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-007-9510-9","volume":"14","author":"B Badgwell","year":"2007","unstructured":"Badgwell B, Feig BW, Ross MI, Mansfield PF, Wen S, Chang GJ (2007) Pneumoperitoneum in the cancer patient. Ann Surg Oncol 14:3141\u20133147","journal-title":"Ann Surg Oncol"},{"key":"581_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4143\/crt.2008.40.1.33","volume":"40","author":"YI Choi","year":"2008","unstructured":"Choi YI, Lee SH, Ahn BK, Baek SU, Park SJ, Kim YS, Shin SH (2008) Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 40:33\u201335","journal-title":"Cancer Res Treat"},{"key":"581_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cursur.2006.06.002","volume":"63","author":"JH Heinzerling","year":"2006","unstructured":"Heinzerling JH, Huerta S (2006) Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63:334\u2013337","journal-title":"Curr Surg"},{"key":"581_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.hoc.2007.03.006","volume":"21","author":"TA Traina","year":"2007","unstructured":"Traina TA, Rugo HS, Dickler M (2007) Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21:303\u2013319","journal-title":"Hematol Oncol Clin North Am"},{"key":"581_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10637-008-9125-4","volume":"26","author":"J Tol","year":"2008","unstructured":"Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investig New Drugs 26:393\u2013397","journal-title":"Investig New Drugs"},{"key":"581_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","volume":"118","author":"DL Richardson","year":"2010","unstructured":"Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM (2010) Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118:47\u201351","journal-title":"Gynecol Oncol"},{"key":"581_CR24","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1200\/JCO.2007.13.6150","volume":"25","author":"SB Kaye","year":"2007","unstructured":"Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25:5150\u20135152","journal-title":"J Clin Oncol"},{"key":"581_CR25","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","volume":"23","author":"HL Kindler","year":"2005","unstructured":"Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033\u20138040","journal-title":"J Clin Oncol"},{"key":"581_CR26","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560\u2013H576","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"581_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","volume":"64","author":"F Lordick","year":"2006","unstructured":"Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64:1295\u20131298","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"581_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ejso.2008.02.013","volume":"35","author":"D Collins","year":"2009","unstructured":"Collins D, Ridgway PF, Winter DC, Fennelly D, Evoy D (2009) Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy. Eur J Surg Oncol 35:444\u2013446","journal-title":"Eur J Surg Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0581-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0581-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0581-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:23:18Z","timestamp":1678558998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0581-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0581-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,14]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}